18 related articles for article (PubMed ID: 2475652)
1. [Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].
Miyazaki E; Takemoto Y; Kanamaru A; Kakishita E; Nagai K; Masaoka T; Shibata H; Horiuti A; Tsubaki K; Yonezawa T
Gan To Kagaku Ryoho; 1992 Apr; 19(4):497-503. PubMed ID: 1558399
[TBL] [Abstract][Full Text] [Related]
2. [Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma].
Arai N; Hara A; Umeda M; Shirai T
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1167-72. PubMed ID: 1711303
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
4. [Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP)].
Sano F; Koike M; Nakamura K; Wakayama T; Kunika N; Kubomatsu Y; Katoh M; Chisa M; Hasegawa S; Takahashi M
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2389-93. PubMed ID: 1463345
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
6. [Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma].
Ohnishi K; Hotta T; Murate T; Inoue C; Ichikawa A; Ninomiya N; Goto S; Tsushita K; Utsumi M; Nagura E
Rinsho Ketsueki; 1989 Mar; 30(3):289-96. PubMed ID: 2475652
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
8. Experience with ifosfamide combinations in malignant lymphomas.
Cabanillas F
Semin Oncol; 1989 Feb; 16(1 Suppl 3):78-81. PubMed ID: 2649986
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]